NCT05859217View on ClinicalTrials.gov

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Lung CancerNSCLC Stage IVMetastatic NSCLC - Non-Small Cell Lung CancerAdvanced NSCLC
Interventions
DRUG

Cabozantinib

Oral once per day, Days 1 - 21 every 21 days

DRUG

Atezolizumab

Intravenous (IV) once every 21 days

Trial Locations (4)

64064

The University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64154

The University of Kansas Cancer Center - North, Kansas City

66205

The University of Kansas Cancer Center - Westwood, Kansas City

66211

The University of Kansas Cancer Center - Indian Creek, Overland Park

Sponsors

Collaborators (2)

Exelixis
Genentech, Inc.
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Jun Zhang, MD, PhD

OTHER

NCT05859217 - A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) | Biotech Hunter | Biotech Hunter